220 / 1631
Cardiovascular disease after therapy for HL:
A detailed analysis of 9 collaborative EORTC-LYSA trials
0
5
10
15
20
25
30
35
40
0
10
Numberof patients at risk:
2811
947
348
108
9
3
0
0
1775
1246
668
304
150
56
26
14
4586
2193
1016
412
159
59
26
14
LSQ responder
LSQ
non-responder
Totalcohort
Totalcohort
4120
1919
6039
Time since treatment start (years)
0
10
20
30
40
50
6039
4586
2193
1045
419
167
63
31
15
Time since treatment start (years)
Cumulative incidence (%)
Numberof patients at risk:
Ischemic heart disease
Congestive heart failure
Pericarditis
Valvular disease
Arrhythmia
Cardiac,other
Stroke
Peripheral vasculopathy
Vascular, other
Disease of arterial vessels
Venous thrombosis
B
0
5
10
15
20
25
30
35
40
Totalcohort
Maraldo et al, Lancet Hemat 2015